ZYNERBA PHARMACEUTICALS, INC.: 10-Q filed 2019-05-08

Name: ZYNERBA PHARMACEUTICALS, INC.: 10-Q filed 2019-05-08
Creator: ZYNERBA PHARMACEUTICALS, INC.

What ZYNERBA PHARMACEUTICALS, INC. reported in its quarterly report filed 2019-05-08 (fiscal Q1 2019): 34 published measures, 68 facts as tagged in accession 0001558370-19-004373.

This filing

Form: 10-Q (quarterly report)
Filed: 2019-05-08
Fiscal period: fiscal Q1 2019
Accession: 0001558370-19-004373 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All ZYNERBA PHARMACEUTICALS, INC. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

Period	Value	Unit	Days
At 2019-03-31	75,517,115	USD
At 2018-12-31	67,327,443	USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

Period	Value	Unit	Days
At 2019-03-31	7,486,381	USD
At 2018-12-31	9,725,782	USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

Period	Value	Unit
At 2019-03-31	68,030,734	USD
At 2018-12-31	57,601,661	USD
At 2018-03-31	50,330,278	USD
At 2017-12-31	60,949,588	USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

Period	Value	Unit	Days
At 2019-03-31	68,299,111	USD
At 2018-12-31	59,763,773	USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	-9,147,017	USD	90
2018-01-01 to 2018-03-31	-12,306,334	USD	90

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	-9,519,844	USD	90
2018-01-01 to 2018-03-31	-10,361,306	USD	90

Capital expenditure payments

Cash payments to acquire property, plant and equipment. This taxonomy concept does not capture every form of investment or acquisition.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	24,616	USD	90
2018-01-01 to 2018-03-31	17,373	USD	90

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	18,079,798	USD	90

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	-24,616	USD	90
2018-01-01 to 2018-03-31	-17,373	USD	90

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

Period	Value	Unit	Days
At 2019-03-31	-127,039,058	USD
At 2018-12-31	-117,892,041	USD

Net property, plant and equipment

Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.

Period	Value	Unit	Days
At 2019-03-31	346,973	USD
At 2018-12-31	371,963	USD

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	1,496,292	USD	90
2018-01-01 to 2018-03-31	1,687,024	USD	90

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	-9,466,369	USD	90
2018-01-01 to 2018-03-31	-12,396,136	USD	90

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

Period	Value	Unit	Days
At 2019-03-31	74,219,102	USD
At 2018-12-31	66,955,480	USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

Period	Value	Unit	Days
At 2019-03-31	7,465,821	USD
At 2018-12-31	9,725,782	USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

Period	Value	Unit	Days
At 2019-03-31	3,947,625	USD
At 2018-12-31	4,461,567	USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	9,466,369	USD	90
2018-01-01 to 2018-03-31	12,396,136	USD	90

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	6,306,712	USD	90
2018-01-01 to 2018-03-31	8,975,513	USD	90

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

Period	Value	Unit	Days
At 2019-03-31	21,074,996	shares
At 2018-12-31	17,626,873	shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

Period	Value	Unit
At 2019-03-31	68,299,111	USD
At 2018-12-31	59,763,773	USD
At 2018-03-31	52,131,598	USD
At 2017-12-31	62,510,277	USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

Period	Value	Unit	Days
At 2019-03-31	195,048,717	USD
At 2018-12-31	175,476,075	USD

Operating lease right-of-use asset

Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.

Period	Value	Unit	Days
At 2019-03-31	258,791	USD

Operating lease liability

Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.

Period	Value	Unit	Days
At 2019-03-31	270,311	USD

Gross property, plant and equipment

Cost of property, plant and equipment before accumulated depreciation. Historical cost does not indicate current value or replacement cost.

Period	Value	Unit	Days
At 2019-03-31	638,889	USD
At 2018-12-31	634,623	USD

Accumulated depreciation on property, plant and equipment

Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.

Period	Value	Unit	Days
At 2019-03-31	291,916	USD
At 2018-12-31	262,660	USD

Accrued current liabilities

Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.

Period	Value	Unit	Days
At 2019-03-31	3,268,445	USD
At 2018-12-31	5,264,215	USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

Period	Value	Unit	Days
At 2019-03-31	2,524,401	USD
At 2018-12-31	3,747,087	USD

Profit or loss including noncontrolling interests

Net income or loss including the portion attributable to noncontrolling interests. It can differ from the net income attributable to the parent that per-share figures use.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	-9,147,017	USD	90
2018-01-01 to 2018-03-31	-12,306,334	USD	90

Net income available to common stockholders

Net income after preferred dividends and similar adjustments, the numerator for basic earnings per share. It can be lower than reported net income.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	-9,147,017	USD	90
2018-01-01 to 2018-03-31	-12,306,334	USD	90

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	3,159,657	USD	90
2018-01-01 to 2018-03-31	3,420,623	USD	90

Depreciation expense

Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	29,256	USD	90
2018-01-01 to 2018-03-31	26,566	USD	90

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	319,352	USD	90
2018-01-01 to 2018-03-31	89,802	USD	90

Operating lease payments

Cash paid for operating lease liabilities during the period. It differs from lease expense recognized and excludes variable payments in some presentations.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	60,894	USD	90

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

Period	Value	Unit	Days
2019-01-01 to 2019-03-31	-510,643	USD	90
2018-01-01 to 2018-03-31	1,250,595	USD	90

Inspect the source

Entity: ZYNERBA PHARMACEUTICALS, INC. / CIK 0001621443
Captured: 2026-09-22 19:53 UTC
SEC response SHA-256: eb291da6063ca15bb79701a29894e4fddd9d66bcb1e18e0733be9f2efb07eaa3

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python

import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001621443.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))